Xcout IntelGelteq Limited competitors & alternatives
The 12 closest competitors and alternatives to Gelteq Limited among pharmaceuticals companies — ranked by similarity to what Gelteq Limited actually does, not by market-cap band.
Subscribe to see Gelteq Limited’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Gelteq Limited
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Gelteq Limited at a glance
Gelteq Limited is a pharmaceuticals company headquartered in Clayton, Australia. It is publicly listed (GELS) with a market capitalisation of $5.6M. Xcout tracks 8 named people at Gelteq Limited, including Adam Bendell (President of U.S. Operations).
Gelteq Limited leadership
- Adam BendellPresident of U.S. Operations
- Thuy-Linh GiglerChief Financial Officer
- Paul WynneChief Scientific Officer
- Nathan Jacob GivoniCo-Founder, Chief Executive Officer & Executive Director
- Simon Hayden SzewachCo-Founder & Non-Executive Chairman
- Bradley Glenn KarpHead of Sales & Marketing
2 more named people on record for Gelteq Limited, with roles, board committees and tenure — see the full roster →
Top 12 Gelteq Limited competitors
Ranked by semantic similarity — how close each company is to Gelteq Limited by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Veterinary Pharmaceuticals
Parnell Pharmaceuticals Holdings Ltd is a global veterinary pharmaceutical company that develops and manufactures medicines and digital technology platforms for livestock and pets. The company serves veterinarians and animal owners by providing pharmaceutical products for anesthesia, sedation, herd health, and reproductive management, alongside specialized on-farm support services.
Similar pharmaceuticals company
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
Similar pharmaceuticals company
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
Similar pharmaceuticals company
Guobang Pharma Ltd., a Chinese company, specializes in the research, development, manufacturing, and distribution of pharmaceutical products for both human and veterinary use within China. For human healthcare, their offerings encompass active pharmaceutical ingredients (APIs), intermediate compounds related to these APIs, and finished dosage forms. In the animal health sector, they provide veterinary APIs, various additives, and prepared formulations. The company was founded in 1996 and has its headquarters situated in Xinchang, China.
Pharmaceuticals, Biotechnology & Life Sciences
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Veterinary Pharmaceuticals
Drag Pharma is a pharmaceutical company that researches, develops, produces, and commercializes veterinary medicines and products for pets and livestock.
Biotech
Biomolecular Life Holdings, Inc. develops and commercializes precision nutrition products, luxury-grade nutritional supplements, and wellness technologies. The company serves both human consumers and the companion animal wellness market with science-backed formulations focused on longevity and preventive health.
Animal Health
In the Bowl Animal Health is a clinical-stage animal health company headquartered in Nashville that utilizes proprietary technology to deliver prescription medicines and treatments.
Life Sciences
Bioniche Life Sciences Inc. was a Canadian biopharmaceutical company focused on developing and commercializing products for human and animal health. It served healthcare providers, patients, livestock producers, veterinarians, and the agricultural industry through pharmaceuticals, vaccines, and related biological products.
Similar pharmaceuticals company
GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) and other non-prescription health solutions. Its diverse product portfolio addresses various common health concerns, featuring: GelStat Migraine, a patented remedy targeting migraine headache pain; Chews 2 Lose, an appetite-controlling gum designed to assist with weight management; All Natural Speed, formulated as an energy booster; and GelStat Sleep, intended to alleviate sleep disturbances and their related symptoms. GelStat distributes its solutions through a comprehensive network, reaching retailers, wholesalers, specialized distributors, and catalog merchandisers. This is achieved both through direct sales and via independent sales brokerage agreements. The corporation maintains its principal office in Palm City, Florida.
Veterinary Pharmaceuticals
Galmedic manufactures and distributes pharmaceutical products for veterinary use across multiple species and international markets.
Similar pharmaceuticals company
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Gelteq Limited and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Gelteq Limitedand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →